Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
作者:
DOI
10.1177/17588359211045845
PMID
34819997
发布时间
2022-04-28
- 浏览0
Therapeutic advances in medical oncology
17588359211045845页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文